Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Sorrento Therape is a biotechnology & medical research business based in the US. Sorrento Therape shares (SRNE) are listed on the NASDAQ and all prices are listed in US Dollars. Sorrento Therape employs 799 staff and has a trailing 12-month revenue of around $60.3 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $0.37 |
|---|---|
| 52-week range | $0.16 - $3.09 |
| 50-day moving average | $0.77 |
| 200-day moving average | $1.55 |
| Wall St. target price | $13.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.53 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.3701 from 2023-03-20
| 1 week (2023-03-14) | 19.50% |
|---|---|
| 1 month (2023-02-21) | -5.10% |
| 3 months (2022-12-21) | -55.52% |
| 6 months (2022-09-21) | -77.43% |
| 1 year (2022-03-21) | -85.25% |
|---|---|
| 2 years (2021-03-19) | -96.13% |
| 3 years (2020-03-20) | 2.05 |
| 5 years (2018-03-21) | 8.1 |
| Revenue TTM | $60.3 million |
|---|---|
| Gross profit TTM | $-167,049,000 |
| Return on assets TTM | -36.87% |
| Return on equity TTM | -378.92% |
| Profit margin | 0% |
| Book value | $0.29 |
| Market capitalisation | $168.4 million |
TTM: trailing 12 months
We're not expecting Sorrento Therape to pay a dividend over the next 12 months.
Sorrento Therape's shares were split on a 1:25 basis on 31 July 2013. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sorrento Therape shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Sorrento Therape shares which in turn could have impacted Sorrento Therape's share price.
Over the last 12 months, Sorrento Therape's shares have ranged in value from as little as $0.161 up to $3.09. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sorrento Therape's is 1.9435. This would suggest that Sorrento Therape's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Sorrento Therapeutics, Inc. , a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.